SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Gwen Ifill

PatientGwen Ifill
Date of birth1965-09-29
IdentifiersMRN HR-ML032-SYN; SSN (made up) 000-32-5814
Document date2026-04-28
AuthorLorna Achebe-Price, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review at the midpoint of combination treatment, on the day of cycle 4. [S]

History of Present Illness

Ms. Ifill returns on the day of her fourth cycle. Cycles 2 and 3 were given on schedule in the infusion center. Nausea lasts a day or two after each cycle and is controlled with ondansetron two or three times. For about two weeks she has had tingling in her toes that does not affect walking or balance. Her hair has thinned and she wears a wig. She has had no diarrhea, rash, cough, breathlessness or headache. She is tired for two or three days after each cycle and works from home on those days. She has had no thoughts of self-harm. [S]

ElementDetail
TreatmentCycle 4 of 6 today; cycles 2 and 3 on schedule
NauseaOne or two days after each cycle; controlled
NeuropathyTingling in the toes for two weeks; no effect on function
Immune-related symptomsNone
MoodPHQ-9 5

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired for two or three days after each cycle; no fever
GastrointestinalPositiveNausea for one or two days after each cycle; no vomiting or diarrhea
NeurologicalPositiveTingling in the toes; no weakness or falls; no headache
IntegumentaryPositiveHair thinning; no rash or itching
RespiratoryNegativeNo cough or breathlessness
EndocrineNegativeNo heat or cold intolerance; no thirst
PsychiatricNegativeMood steady; no thoughts of self-harm

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-02-03 to 2026-02-17completedS
Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2026-02-24 to 2026-06-30completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-28Body height165cmS
2026-04-28Body weight71.8kgS
2026-04-28Body mass index (BMI) [Ratio]26.4kg/m2S
2026-04-28Systolic blood pressure120mm[Hg]S
2026-04-28Diastolic blood pressure76mm[Hg]S
2026-04-28Heart rate82/minS
2026-04-28Respiratory rate16/minS
2026-04-28Body temperature36.6CelS
2026-04-28Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-28Hemoglobin [Mass/volume] in Blood10.6g/dL12-15.5 g/dLLowS
2026-04-28Leukocytes [#/volume] in Blood by Automated count4.310*3/uL4-11 10*3/uLNormalS
2026-04-28Neutrophils [#/volume] in Blood by Automated count2.110*3/uL1.5-7.7 10*3/uLNormalS
2026-04-28Platelets [#/volume] in Blood by Automated count19610*3/uL150-400 10*3/uLNormalS
2026-04-28Creatinine [Mass/volume] in Serum or Plasma0.81mg/dL0.59-1.04 mg/dLNormalS
2026-04-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M83mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-28Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
2026-04-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
2026-04-28Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L8-35 U/LNormalS
2026-04-28Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-04-28Magnesium [Mass/volume] in Serum or Plasma1.8mg/dL1.7-2.2 mg/dLNormalS
2026-04-28Thyrotropin [Units/volume] in Serum or Plasma4.8m[IU]/L0.4-4.5 mIU/LHighS
2026-04-28Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
2026-04-28Cortisol [Mass/volume] in Serum or Plasma12.6ug/dLMorning sample, drawn before 9 a.m.NormalS
2026-04-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S

Physical Exam

Vital signs recorded on 2026-04-28; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 71.8 kg; blood pressure 120/76, pulse 82
AbdomenSoft, non-tender; no mass
ExtremitiesNo leg swelling; calf circumferences unchanged
NeurologicalPinprick slightly reduced over the toes; vibration sense and ankle reflexes present; strength normal; steady gait
SkinHair thinning; no rash
PsychiatricEngaged and composed

Problems

ProblemClinical statusVerificationCodeProvenance
Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review bookedresolvedconfirmed N95.0S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation.
Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial canceractiveconfirmed C54.1S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public.
Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2023 stage IIIC2iiactiveconfirmed C77.8S — Synthetic nodal disease found at surgical staging.
Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities)activeconfirmed G62.0S — Synthetic common effect of paclitaxel.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with neutrophils and plateletsBefore each chemotherapy cycleCompleted todayHemoglobin 10.6 g/dL, white cells 4.3, neutrophils 2.1, platelets 196; cycle 4 can be given. Cycles 2 and 3 were given on schedule in the infusion center
LaboratoryCreatinine and estimated kidney function (carboplatin dose)Before each cycleCompleted todayCreatinine 0.81 mg/dL, eGFR 83; carboplatin dose unchanged
LaboratoryLiver tests (paclitaxel and checkpoint inhibitor)Baseline and before each checkpoint inhibitor doseCompleted todayALT 24, AST 26 U/L, bilirubin 0.5 mg/dL
LaboratoryMagnesiumBefore each cycleCompleted today1.8 mg/dL
LaboratoryTSH and free T4 (immune-related thyroid disease)Baseline and before each checkpoint inhibitor doseCompleted todayTSH 4.8 mIU/L, just above range, with free T4 1.1 ng/dL: watch before each cycle
LaboratoryGlucose (immune-related diabetes)Baseline and before each checkpoint inhibitor doseCompleted today97 mg/dL
LaboratoryMorning cortisol (immune-related adrenal and pituitary disease)Baseline and before each checkpoint inhibitor doseDeferred12.6 ug/dL today, normal. A deviation: the baseline cortisol deferred at cycle 1 was not drawn before cycles 2 and 3 either, because the request was not carried into the infusion center's standing orders. No harm resulted: today's value is normal and she has had no symptom of adrenal insufficiency. Corrective action: morning cortisol added to the standing orders before every remaining dose; no earlier values are recorded
ExaminationPeripheral neuropathy: symptoms and examinationBaseline and before each taxane cycleCompleted todayGrade 1 sensory neuropathy; full dose continues
ExaminationLymphedemaEach visit after lymph node surgeryCompleted todayNo swelling; calf measurements unchanged
ExaminationImmune-related adverse event symptoms (diarrhea, rash, cough, breathlessness, fatigue, headache)Each visit on a checkpoint inhibitorCompleted todayNone reported; skin and chest normal
ImagingResponse imagingAt the end of combination treatment, or sooner for symptomsNot indicatedNot needed at the midpoint after complete resection, with no symptoms; CT after cycle 6
Medication safetyNausea and vomiting controlEach cycleCompleted todayControlled: nausea one or two days per cycle, no vomiting
Medication safetyPaclitaxel infusion reaction preventionEach paclitaxel doseCompleted todayNo reaction in three cycles; same premedication
SurveyDistress and depression screen (PHQ-9)At diagnosis, each treatment phase, and when symptoms changeCompleted todayPHQ-9 5

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023); JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026); Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Cycles 5 and 6 every 21 days, with TSH, free T4 and a morning cortisol before each. CT about two weeks after cycle 6, then a review with the result and the first maintenance dose. Next scheduled visit 2026-06-30: end of combination treatment: response CT, immune-related hypothyroidism, the first maintenance dostarlimab dose, and the survivorship plan. [S]